New migraine options needed
The American Migraine Prevalence and Prevention (AMPP) Study recommends new options for those with cardiovascular event histories who also need migraine treatment
Almost 5 million Americans with episodic migraine (EM) should not be prescribed a triptan, the only class of acute medications FDA approved and developed for migraine, because of the presence of cardiovascular contraindications, according to results from the American Migraine Prevalence and Prevention (AMPP) study.
The results of the study were presented in June at the 2013 International Headache Congress in Boston.
“Triptans are widely prescribed and effective; however their use is contraindicated with persons with cardiovascular [CV] event histories and conditions,” according to Dawn Buse, PhD, associate professor of neurology, Albert Einstein College of Medicine, Montefiore Headache Center, New York City. “This leaves a substantial number of individuals without safe and effective treatment for migraine. Awareness of this unmet need and the resulting need for safe and effective therapies for this large group of patients is vital to the effective care of persons with migraine.”
The study analyzed 6,723 patients with EM.
CV Events and Procedures
Aged <40
Aged 40-59
Aged ≥60
Myocardial Infarction
6 (0.4%)
112 (3.4%)
104 (8%)
TIA
17 (1.2%)
135 (3.9%)
101 (7.2%)
Stroke
11 (0.8%)
72 (2.1%)
76 (5.4%)
Claudication
85 (6.2%)
294 (8.6%)
182 (13.1%)
Angina
58 (4.2%)
271 (7.9%)
192 (13.7%)
Coronary Bypass Surgery
11 (0.8%)
41 (1.1%)
49 (3.2%)
Coronary Angioplasty/Stenting
15 (1.0%)
114 (3.1%)
100 (6.5%)
Carotid Artery Surgery/Stenting
10 (0.7%)
28 (0.8%)
22 (1.4%)
Peripheral Artery Bypass Surgery
10 (0.7%)
32 (0.9%)
16 (1%)
Respondents with ≥1 Event/Procedure
151 (11.1%)
623 (18.7%)
460 (33.6%)
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
